Navigation Links
SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Italy

SAN DIEGO, June 9 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that it has established a distribution partnership for the Italian market through Medimar Italia, a Milan-based firm specializing in medical device sales in the country.

Michel Vaudry, SpectraScience's Director of International Sales commented that, "We are pleased to have added our second European distributor in the past two months. Medimar is a respected and well-established medical device distributor and its decision to add the WavSTAT Optical Biopsy System to their portfolio is a strong validation of our technology."

Medimar's President, Francesco Torelli, stated that, "SpectraScience's WavSTAT cancer diagnosis system has tremendous potential to impact the marketplace here in Italy. The importance of earlier and more effective screening for colon cancer cannot be stressed enough and we look forward to representing the product and working with SpectraScience to establish and build a strong Italian market presence."

Vaudry added that, "Mr. Torelli is a respected thought leader in the medical device market in Italy, so his support of the WavSTAT System will be instrumental in our acceptance into the major gastroenterology centers in the country."
Key Benefits to the WavSTAT Optical Biopsy System

-- Helps the physician discern between normal and pre-cancerous tissue in

the GI tract

-- Gives the physician additional information that allows for a more

informed decision on leaving polyps on site if they are not

pre-cancerous thereby minimizing risks and time.

-- Provides the opportunity for physicians to perform a physical biopsy at

exactly the same site and time that the optical biopsy is performed

-- Allows physicians to determine the margin, or border of the

pre-cancerous tissue

-- Aids physicians during colon cancer surgery to determine if all

cancerous tissue has been removed

-- Is complementary to NBI and Smart Pill and other recent evaluating

technologies (e.g. Olympus, Pentax, Fujinon, Given).

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward- looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provides the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA(R) cervical imaging technology has received FDA approval as an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available today.


SpectraScience, Inc.

Jim Hitchin, Chief Executive Officer

(858) 847-0200 x201

Hayden Communications

Investor Relations

Todd Pitcher

(858) 518-1387

SOURCE SpectraScience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. SpectraScience Receives Final European Certification
2. SpectraScience Acquires Luma Imaging Corporation
3. SpectraScience, Inc. Retains Hayden Communications
4. SpectraScience Secures Distribution for WavSTAT(R) System in Czech Republic
5. BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB
6. Simplex Diabetic Supply, Inc. Secures $50 Million in Growth Equity from New Enterprise Associates
7. UI licensee Optherion secures $37 million in financing
8. IPS Secures National Contract to Deliver FOCUS Healthcare Provider Network Access to Pain Management Specialists
9. Piedmont Pharmaceuticals Secures $8.5 Million Investment
10. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
11. Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology: